Radiomics involves deep quantitative analysis of radiological images for structural and/or functional information. – It is a phenomic assessment of disease to understand lesion microstructure, microenvironment and molecular/cellular function. – In oncology, it helps us accurately classify, stratify and prognosticate tumors based on if, how and when they transform, infiltrate, involute or metastasize, – Utilizing radiomics in clinical trials is exploratory, and not an established end-point. – Integrating radiomics in an imaging-based clinical trials involves a streamlined workflow to handle large datasets, robust platforms to accommodate machine learning calculations, and seamless incorporation of derived insights into outcomes matrix.
Radiomics in Clinical Trials – The Rationale, Current Practices, and Future Considerations
December 6, 2019
Radiology Society of North America
F. Shaikh, MD, PA; D Roettger, PhD; E Kurtys; O A Awan, MD; O A Kubassova, PhD